President, CEO, and Director, Travere Therapeutics
Eric Dube has a wealth of industry experience; he served as the president and head of North America at ViiV Healthcare and spent more than 18 years working in roles of increasing leadership at GlaxoSmithKline across the US, Europe, and Japan. In his current role, Dube works on developing life-changing therapies for people living with rare diseases. He has won several awards during his career, including being named one of 100 OUTstanding LGBT+ Executives in the Financial Times.
What was the most serendipitous moment in your career?
The opportunity to lead Travere. It’s serendipitous that as a survivor of a rare cancer, I am leading an organization developing therapies for rare diseases. I was 30 years old when my doctor told me, “Eric, let's hope your surgery goes well because there are no approved therapies for this cancer, and you are the seventh person to be diagnosed.” I still remember that moment vividly and it motivates me to deliver innovation in rare disease, so that no other family has to hear that there is not an approved treatment for them. That is what drives us at Travere.
I was diagnosed just as I was starting my career. Similarly, the rare conditions Travere is working in can strike at this age and younger. IgA nephropathy, a rare kidney disease (RKD), attacks the kidneys, typically manifesting in adults in their 20s and 30s. Following a sometimes-long road to diagnosis and treatment, many still progress to kidney failure which can mean dialysis or transplantation in their 30s or 40s.
I’m proud to be leading a team that works day in and out to bring innovative new treatment options to patients. With a pipeline of potential treatment options for people living with rare kidney and metabolic disease, we are making progress to potentially change the health trajectory of people’s lives.